Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Summary

Official Title

A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)

Keywords

Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing, EGFR PACC, EGFR Uncommon Mutations, Non-Small Cell Lung Cancer (NSCLC), PACC, Firmonertinib, Furmonertinib, AST2818, FURMO-006, Drug-Therapy, Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, NSCLC, Osimertinib, Afatinib, metastatic NSCLC first-line treatment, Carcinoma NSCLC, Respiratory tract neoplasms, Bronchial Neoplasms, Protein Kinase Inhibitors, tyrosine kinase inhibitor (TKI), Alflutinib, Lung neoplasms, EGFR kinase domain mutations, EGFR activating mutation, EGFR mutation of unknown significance, Non-classical EGFR mutation, EGFR atypical mutations, EGFR, G719X, S7681, E709X, E709_T710delinsD, G779F, L747X, V774M, L747P/S, R776C/H, G724S, E736K, 1740_K745dup, N771G, K757M/R, V769L/M, Non-Small-Cell Lung Carcinoma, aflutinib, EGFR-TKI inhibitor based on investigator's choice, Firmonertinib 240 mg